Last updated: May 1, 2026
Who supplies desogestrel and ethinyl estradiol at API scale?
Desogestrel and ethinyl estradiol are commonly sourced as Active Pharmaceutical Ingredients (APIs) from multinational and specialty API manufacturers. For finished-dose combination products (oral contraceptives), sourcing typically happens through API distributors or direct API procurement from API manufacturers with DMF/ASMF support for regulatory filings.
Typical supplier archetypes (market practice)
- API manufacturers (chemical synthesis or semi-synthesis routes; provide DMF/ASMF)
- API traders/distributors (cross-supply from multiple API plants; offer compliance documentation)
- Contract manufacturers (API intermediates) feeding into final API sites
Regulatory-document-driven shortlist
In contraceptive combinations containing desogestrel + ethinyl estradiol, the most defensible supplier set for qualification is determined by:
- DMF/ASMF holders for the exact API (polymorph/particle-size specifications can matter)
- cGMP batch record availability and audit history for the API site
- traceability for starting materials and intermediates (especially for estradiol-derived or steroid-like synthesis routes)
Which countries and supplier types dominate supply?
Supply is concentrated in Asia-based API manufacturing hubs and in a smaller set of Europe/Japan-based specialty API providers. The market for steroid-like hormones is constrained by:
- controlled synthesis know-how
- fermentation-to-steroid or semi-synthetic availability
- stringent regulatory expectations for impurity profiles
Procurement implication
For business-critical programs, suppliers are usually selected from:
- companies that already file with US FDA (DMF) or with EMA (ASMF)
- companies that can furnish full batch release data, impurity specs, and residual solvent profiles to match pharmacopeial monographs and finished-product needs
What are the most common supply forms used in procurement?
For combination oral contraceptives, procurement usually targets:
- Desogestrel API (usually in defined particle size range or with impurity controls aligned to pharmacopeia and clinical-grade specs)
- Ethinyl estradiol API (with tight control of related substances)
- sometimes desogestrel intermediates and estradiol/ethinyl estradiol intermediates via CMO plants, depending on whether a firm integrates early steps
Quality-critical specs to request up front (procurement checklist)
- impurity list and specification acceptance criteria
- residual solvents and Class limits
- polymorph/hydrate form and evidence method
- particle size distribution (PSD) and water content
- CoA format, analytical methods, and reference standards
Who are the supplier categories used in due diligence for contraceptive APIs?
When buyers qualify desogestrel and ethinyl estradiol, due diligence usually focuses on the API site, not just the brand label on the CoA.
API site diligence points
- cGMP certification status and inspection history for the API plant
- DMF/ASMF match to the exact manufacturer and synthetic route
- batch release and stability package availability
- ability to support tech transfer and method validation
Distributor diligence points
- chain-of-custody controls and temperature/time controls (if applicable)
- ability to provide CoA traceable to original manufacturer lots
- regulatory letter support and documentation package completeness
What are the key compliance documents that map to supplier eligibility?
In practice, supplier eligibility for desogestrel and ethinyl estradiol depends on possession or sponsorship of regulatory dossiers:
- US FDA DMF (Drug Master File) for each API (and sometimes intermediates) tied to a named site
- EU ASMF for each API (tied to an approved manufacturing site)
- CEP (Certificate of Suitability) if applicable to the API monograph
- CoA, impurity profiles, residual solvent compliance, and stability summaries
Why supplier selection can fail even when the API is “available”?
Common failure modes in desogestrel and ethinyl estradiol supply qualification:
- mismatched impurity profiles to the finished-dose product requirements
- lack of consistent polymorph control or PSD consistency
- dossier-holder mismatch (DMF/ASMF held by one entity while API ships from another)
- insufficient method transfer support (analytical methods not transferable or validated for the buyer’s QC system)
Key Takeaways
- Desogestrel + ethinyl estradiol supply is dossier- and site-specific. Qualify against DMF/ASMF and manufacturing site identity, not only supplier branding.
- The supplier set is typically a mix of API manufacturers and compliance-forward distributors. Shortlists should be built from dossier holders and plants with stable impurity control and PSD/polymorph consistency.
- Procurement success depends on analytical and impurity spec alignment (residual solvents, related substances, and solid-state form) with finished-dose registration needs.
FAQs
1) Are desogestrel and ethinyl estradiol usually sold as APIs only, or also as intermediates?
Both exist in the market. Buyers often source finished APIs, but intermediates are used when integrating synthesis or when qualifying to specific impurity-controlled routes.
2) What documents matter most when selecting a supplier for these hormones?
The practical gatekeepers are DMF/ASMF alignment, CoA traceability to the correct manufacturing site, impurity specification sheets, residual solvent compliance, and stability data.
3) Can a distributor supply the same API regardless of manufacturer?
No. A distributor may sell the same labeled API, but regulatory acceptance depends on the actual manufacturing site and dossier linkage to that site.
4) What quality attributes most often trigger qualification failures?
Impurity profile differences, residual solvent variance, and solid-state behavior (polymorph/hydrate) or particle-size distribution differences.
5) What is the fastest path to qualifying a new supplier?
Use a supplier that can tie batches to the exact dossier (DMF/ASMF) for the API and provide full method transfer and impurity specification documentation aligned to pharmacopeial expectations and finished-dose needs.
References
[1] US Food and Drug Administration. Drug Master Files (DMF). https://www.fda.gov/drugs/drug-master-files-dmf
[2] European Medicines Agency. Active Substance Master File Procedure (ASMF). https://www.ema.europa.eu/en/human-regulatory/research-development/active-substance-master-file-procedure
[3] European Directorate for the Quality of Medicines & HealthCare (EDQM). Certificates of Suitability to the Monographs of the European Pharmacopoeia (CEP). https://www.edqm.eu/en/certificates-suitability-monographs-european-pharmacopoeia-cep
